Page 457 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

Appendix Table C4.1. Descriptive characteristics of the randomized controlled trials and comparative cohort studies considered
relevant to KQ4 (continued)
Author, Year Study name Comparison Study Sample Inclusion criteria Population description: Quality
[Pubmed ID] /Database duration size (total) Age Comments
PSA (ng/mL)
Study design Tumor grade
Stage
Fransson 225 Ancillary WW vs. RT Median 72 (54 Localized prostate cancer Median age (range): WW, 78 C
2009 investigation followup responders) patients, no previous treatment (65-88); RT, 77 (54-87)
18985545 from UMEA1 (range): for prostate cancer, no comorbid Only 72 out
trial WW, 114 condition that would result in PSA: WW, ≤10, 37%; 11-20, of original
RCT mo (95- expected survival less than that 7%; 21-50, 26%, >50, 15%; 166
196); RT, of the normal population of the unknown, 15%. RT, ≤10, 26%; patients in
118 mo same age 11-20, 26%; 21-50, 26%, >50, the trial
(77-188) 4%; unknown, 19% were
included in
Grade: WW, WHO 1, 78%; this study.
WHO 2, 22%. RT, WHO 1,
70%; WHO 2, 30%, unknown,
1%

Stage: WW, T1a, 15%; T1b,
19%; T1c, 0%; T2, 78%. RT,
T1a, 0%; T1b, 15%; T1c, 4%;
T2, 81%.

C-146